{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T19:46:05Z","timestamp":1787600765700,"version":"build-2736575974"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T00:00:00Z","timestamp":1724716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T00:00:00Z","timestamp":1724716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s11096-024-01786-y","type":"journal-article","created":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T08:30:38Z","timestamp":1724747438000},"page":"1525-1535","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Group-based trajectory modeling to identify adherence patterns for direct oral anticoagulants in Medicare beneficiaries with atrial fibrillation: a real-world study on medication adherence"],"prefix":"10.1007","volume":"46","author":[{"given":"Anjana","family":"Mohan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish A.","family":"Deshmukh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Wanat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekere James","family":"Essien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rutugandha","family":"Paranjpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bilqees","family":"Fatima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8779-8523","authenticated-orcid":false,"given":"Susan","family":"Abughosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,27]]},"reference":[{"key":"1786_CR1","doi-asserted-by":"crossref","unstructured":"Kamel H, Healey JS. Cardioembolic stroke. Circ Res. 2017; 120: 514\u201326. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28154101","DOI":"10.1161\/CIRCRESAHA.116.308407"},{"key":"1786_CR2","doi-asserted-by":"crossref","unstructured":"Mumoli N, Mastroiacovo D, Tamborini-Permunian E, et al. Dabigatran in nonvalvular atrial fibrillation: from clinical trials to real-life experience. J Cardiovasc Med. (Hagerstown). 2017; 18: 467\u201377. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28509761","DOI":"10.2459\/JCM.0000000000000524"},{"key":"1786_CR3","doi-asserted-by":"crossref","unstructured":"Colilla S, Crow A, Petkun W, et al. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol. 2013; 112: 1142\u201347. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23831166","DOI":"10.1016\/j.amjcard.2013.05.063"},{"key":"1786_CR4","doi-asserted-by":"crossref","unstructured":"Contreras JP, Hong KN, Castillo J, et al. Anticoagulation in patients with atrial fibrillation and heart failure: Insights from the NCDR PINNACLE-AF registry. Clin Cardiol. 2019; 42: 339\u201345. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30582177","DOI":"10.1002\/clc.23142"},{"key":"1786_CR5","doi-asserted-by":"crossref","unstructured":"Johnson ME, Lefevre C, Collings SL, et al. Early real-world evidence of persistence on oral anticoagulants for stroke prevention in non-valvular atrial fibrillation: a cohort study in UK primary care. BMJ Open. 2016; 6: e011471. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27678530","DOI":"10.1136\/bmjopen-2016-011471"},{"key":"1786_CR6","doi-asserted-by":"crossref","unstructured":"An J, Bider Z, Luong TQ, et al. Long-term medication adherence trajectories to direct oral anticoagulants and clinical outcomes in patients with atrial fibrillation. J Am Heart Assoc. 2021; 10: e021601. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34713708","DOI":"10.1161\/JAHA.121.021601"},{"key":"1786_CR7","doi-asserted-by":"crossref","unstructured":"Conway SE, Hwang AY, Ponte CD, et al. Laboratory and clinical monitoring of direct acting oral anticoagulants: what clinicians need to know. Pharmacotherapy. 2017; 37: 236\u201348. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27983747","DOI":"10.1002\/phar.1884"},{"key":"1786_CR8","doi-asserted-by":"crossref","unstructured":"Brown JD, Shewale AR, Talbert JC. Adherence to rivaroxaban, dabigatran, and apixaban for stroke prevention in incident, treatment-naive nonvalvular atrial fibrillation. J Manag Care Spec Pharm. 2016; 22: 1319\u201329. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27783556","DOI":"10.18553\/jmcp.2016.22.11.1319"},{"key":"1786_CR9","doi-asserted-by":"crossref","unstructured":"McHorney CA, Ashton V, Laliberte F, et al. Adherence to rivaroxaban compared with other oral anticoagulant agents among patients with nonvalvular atrial fibrillation. J Manag Care Spec Pharm. 2017; 23: 980\u201388. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28854075","DOI":"10.18553\/jmcp.2017.23.9.980"},{"key":"1786_CR10","doi-asserted-by":"crossref","unstructured":"Chen N, Brooks MM, Hernandez I. Latent classes of adherence to oral anticoagulation therapy among patients with a new diagnosis of atrial fibrillation. JAMA Netw Open. 2020; 3: e1921357. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32074287","DOI":"10.1001\/jamanetworkopen.2019.21357"},{"key":"1786_CR11","doi-asserted-by":"crossref","unstructured":"Hernandez I, He M, Chen N, et al. Trajectories of oral anticoagulation adherence among medicare beneficiaries newly diagnosed with atrial fibrillation. J Am Heart Assoc. 2019; 8: e011427. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31189392","DOI":"10.1161\/JAHA.118.011427"},{"key":"1786_CR12","doi-asserted-by":"crossref","unstructured":"Salmasi S, De Vera MA, Safari A, et al. Longitudinal oral anticoagulant adherence trajectories in patients with atrial fibrillation. J Am Coll Cardiol. 2021; 78: 2395\u201304. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34886959","DOI":"10.1016\/j.jacc.2021.09.1370"},{"key":"1786_CR13","first-page":"408","volume":"30","author":"B Fatima","year":"2024","unstructured":"Fatima B, Mohan A, Altaie I, et al. Predictors of adherence to direct oral anticoagulants after cardiovascular or bleeding events in Medicare Advantage Plan enrollees with atrial fibrillation. J Manag Care Spec Pharm. 2024;30:408\u201319.","journal-title":"J Manag Care Spec Pharm"},{"key":"1786_CR14","doi-asserted-by":"crossref","unstructured":"Paranjpe R, Johnson ML, Essien EJ, et al. Group-based trajectory modeling to identify patterns of adherence and its predictors among older adults on angiotensin-converting enzyme inhibitors (aceis)\/angiotensin receptor blockers (arbs). patient prefer adherence. 2020; 14: 1935\u201347. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/33116437","DOI":"10.2147\/PPA.S270809"},{"key":"1786_CR15","unstructured":"Vadhariya A, Fleming ML, Johnson ML, et al. Group-based trajectory models to identify sociodemographic and clinical predictors of adherence patterns to statin therapy among older adults. Am Health Drug Benefits. 2019; 12: 202\u201311. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31428238"},{"key":"1786_CR16","unstructured":"Manual MMC. Medicare Managed Care Manual. Centers for medicare & medicaid services; 2014, 4th Oct 2023 Accessed. https:\/\/www.cms.gov\/Regulations-and-Guidance\/Guidance\/Manuals\/Downloads\/mc86c07.pdf"},{"key":"1786_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40545-021-00385-w","volume":"14","author":"D Prieto-Merino","year":"2021","unstructured":"Prieto-Merino D, Mulick A, Armstrong C, et al. Estimating proportion of days covered (PDC) using real-world online medicine suppliers\u2019 datasets. J Pharm Policy Pract. 2021;14:1\u201314.","journal-title":"J Pharm Policy Pract"},{"key":"1786_CR18","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1007\/s11096-022-01417-4","volume":"44","author":"A Mohan","year":"2022","unstructured":"Mohan A, Majd Z, Trinh T, et al. Group based trajectory modeling to assess adherence to oral anticoagulants among atrial fibrillation patients with comorbidities: A retrospective study. Int J Clin Pharm. 2022;44:966\u201374.","journal-title":"Int J Clin Pharm"},{"key":"1786_CR19","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1097\/MLR.0000000000001625","volume":"59","author":"RP Hickson","year":"2021","unstructured":"Hickson RP, Annis IE, Killeya-Jones LA, et al. Comparing continuous and binary group-based trajectory modeling using statin medication adherence data. Med Care. 2021;59:997\u201305.","journal-title":"Med Care"},{"key":"1786_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-045018","volume":"11","author":"M Lederle","year":"2021","unstructured":"Lederle M, Tempes J, Bitzer EM. Application of Andersen\u2019s behavioural model of health services use: a scoping review with a focus on qualitative health services research. BMJ Open. 2021;11: e045018.","journal-title":"BMJ Open"},{"key":"1786_CR21","unstructured":"Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases and risk factors, 1990\u20132019: Update from the GBD 2019 Study. J Am Coll Cardiol. 2020; 76: 2982\u201321. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/33309175"},{"key":"1786_CR22","doi-asserted-by":"crossref","unstructured":"Gosselin RC, Adcock DM, Douxfils J. An update on laboratory assessment for direct oral anticoagulants (DOACs). Int J Lab Hematol. 2019; 41 Suppl 1: 33\u201339. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31069969","DOI":"10.1111\/ijlh.12992"},{"key":"1786_CR23","doi-asserted-by":"crossref","unstructured":"Manzoor BS, Lee TA, Sharp LK, et al. Real-world adherence and persistence with direct oral anticoagulants in adults with atrial fibrillation. pharmacotherapy. 2017; 37: 1221\u201330. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28730619","DOI":"10.1002\/phar.1989"},{"key":"1786_CR24","doi-asserted-by":"crossref","unstructured":"McHorney CA, Crivera C, Laliberte F, et al. Adherence to rivaroxaban versus apixaban among patients with non-valvular atrial fibrillation: Analysis of overall population and subgroups of prior oral anticoagulant users. PLoS One. 2018; 13: e0194099. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29621248","DOI":"10.1371\/journal.pone.0194099"},{"key":"1786_CR25","doi-asserted-by":"crossref","unstructured":"Borne RT, O'Donnell C, Turakhia MP, et al. Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: findings from the veterans health administration. BMC Cardiovasc Disord. 2017; 17: 236. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28865440","DOI":"10.1186\/s12872-017-0671-6"},{"key":"1786_CR26","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.annemergmed.2022.03.010","volume":"80","author":"S Islam","year":"2022","unstructured":"Islam S, Dover DC, Daniele P, et al. Sex differences in the management of oral anticoagulation and outcomes for emergency department presentation of incident atrial fibrillation. Ann Emerg Med. 2022;80:97\u2013107.","journal-title":"Ann Emerg Med"},{"key":"1786_CR27","doi-asserted-by":"crossref","unstructured":"Kirkman MS, Rowan-Martin MT, Levin R, et al. Determinants of adherence to diabetes medications: findings from a large pharmacy claims database. Diabetes Care. 2015; 38: 604\u201309. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25573883","DOI":"10.2337\/dc14-2098"},{"key":"1786_CR28","doi-asserted-by":"crossref","unstructured":"Mohan A, Vadhariya A, Majd Z, et al. Impact of a motivational interviewing intervention targeting statins on adherence to concurrent hypertension or diabetes medications. Patient Educ Couns. 2021; 104: 1756\u201364. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/33402279","DOI":"10.1016\/j.pec.2020.12.009"},{"key":"1786_CR29","doi-asserted-by":"crossref","unstructured":"Beyer-Westendorf J, Forster K, Ebertz F, et al. Drug persistence with rivaroxaban therapy in atrial fibrillation patients-results from the Dresden non-interventional oral anticoagulation registry. Europace. 2015; 17: 530\u201338. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25694537","DOI":"10.1093\/europace\/euu319"},{"key":"1786_CR30","doi-asserted-by":"crossref","unstructured":"Banerjee A, Benedetto V, Gichuru P, et al. Adherence and persistence to direct oral anticoagulants in atrial fibrillation: a population-based study. Heart. 2020; 106: 119\u201326. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31601729","DOI":"10.1136\/heartjnl-2019-315307"},{"key":"1786_CR31","doi-asserted-by":"crossref","unstructured":"Deshpande CG, Kogut S, Willey C. Real-world health care costs based on medication adherence and risk of stroke and bleeding in patients treated with novel anticoagulant therapy. J Manag Care Spec Pharm. 2018; 24: 430\u201339. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29694285","DOI":"10.18553\/jmcp.2018.24.5.430"},{"key":"1786_CR32","doi-asserted-by":"crossref","unstructured":"Perreault S, de Denus S, White-Guay B, et al. Oral anticoagulant prescription trends, profile use, and determinants of adherence in patients with atrial fibrillation. Pharmacotherapy. 2020; 40: 40\u201354. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31758592","DOI":"10.1002\/phar.2350"},{"key":"1786_CR33","doi-asserted-by":"crossref","unstructured":"Arbel A, Abu-Ful Z, Preis M, et al. Adherence with direct oral anticoagulants in patients with atrial fibrillation: Trends, risk factors, and outcomes. J Arrhythm. 2022; 38: 67\u201376. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/35222752","DOI":"10.1002\/joa3.12656"},{"key":"1786_CR34","doi-asserted-by":"crossref","unstructured":"Smits E, Andreotti F, Houben E, et al. Adherence and persistence with once-daily vs twice-daily direct oral anticoagulants among patients with atrial Fibrillation: Real-World Analyses from the Netherlands, Italy and Germany. Drugs-real world outcomes. 2022: 1\u201311.","DOI":"10.1007\/s40801-021-00289-w"},{"key":"1786_CR35","doi-asserted-by":"crossref","unstructured":"Abughosh SM, Vadhariya A, Johnson ML, et al. Enhancing statin adherence using a motivational interviewing intervention and past adherence trajectories in patients with suboptimal adherence. J Manag Care Spec Pharm. 2019; 25: 1053\u201362. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31556824","DOI":"10.18553\/jmcp.2019.25.10.1053"},{"key":"1786_CR36","doi-asserted-by":"crossref","unstructured":"Abughosh SM, Wang X, Serna O, et al. A pharmacist telephone intervention to identify adherence barriers and improve adherence among nonadherent patients with comorbid hypertension and diabetes in a medicare advantage plan. J Manag Care Spec Pharm. 2016; 22: 63\u201373. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27015053","DOI":"10.18553\/jmcp.2016.22.1.63"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-024-01786-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-024-01786-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-024-01786-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T21:09:19Z","timestamp":1732050559000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-024-01786-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,27]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["1786"],"URL":"https:\/\/doi.org\/10.1007\/s11096-024-01786-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3938126\/v1","asserted-by":"object"}]},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,27]]},"assertion":[{"value":"7 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"For this study all authors have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}